Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 0.080 | 0.029 | 0.207 |
| 2025 |
|---|
| 20.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 0.080 | 0.029 | 0.207 |
| 2025 |
|---|
| 20.7% |
The Oakmark Global Select Fund delivered a 2.91% return in Q4 2025, underperforming the MSCI World Index's 3.12% return, though achieving strong full-year performance of 20.71%. The fund maintains a concentrated global portfolio with 55.6% in the U.S., 31.4% in Europe ex-U.K., and selective emerging market exposure at 3.6%. Healthcare and financials were the strongest performing sectors, while consumer discretionary and staples detracted. Bayer led performance with positive drug trial results for Asundexian and potential Supreme Court review of litigation matters. Alibaba declined despite strong core e-commerce and accelerating cloud growth, pressured by Quick Commerce investment spending. The managers added Sanofi, capitalizing on temporary vaccine market volatility to invest in a company with the blockbuster drug Dupixent and strong R&D pipeline. Portfolio activity included exits from Mercedes-Benz and Roche. The strategy continues focusing on undervalued companies with strong fundamentals where temporary market concerns create attractive entry points for long-term value creation.
The fund focuses on undervalued global companies with strong fundamentals, particularly in pharmaceuticals and technology, where temporary market concerns create opportunities to invest in businesses with long-term growth potential and competitive advantages.
The managers express optimism about pharmaceutical companies with strong R&D pipelines and expect vaccine markets to normalize. They maintain conviction in Chinese technology companies despite near-term headwinds, believing in long-term value creation through AI capabilities and market positioning.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 13 2026 | 2025 Q4 | BABA, BAYRY, CHTR, CNHI, GOOGL, IQV, MBG.DE, RHHBY, SNY | China, Europe, global, healthcare, Pharmaceuticals, technology, value |
BAYN GR BABA SAN FP |
The fund is positioned in pharmaceutical companies with strong fundamentals and growth potential. Bayer benefited from positive drug trial results and potential Supreme Court review… |
| Oct 10 2025 | 2025 Q3 | BABA, CHTR, DSY FP | AI, Broadband, Cloud, innovation, Virtual Twin | - | The letter highlights selective exposure to global technology and communication firms such as Alibaba and Charter, emphasizing AI-led growth and virtual twin software as durable… |
| Jun 30 2025 | 2025 Q2 | - | healthcare, industrials, Quality, value | - | - |
| Mar 31 2025 | 2025 Q1 | GOOG, LYG, MOH, SYY | - | - | - |
| Dec 31 2024 | 2024 Q4 | BAYN GR, COF, DEO, ELV, SCHW | - | - | - |
| Sep 30 2024 | 2024 Q3 | 005935 KS | - | - | - |
| Jun 30 2024 | 2024 Q2 | CNH, GOOG | - | - | - |
| Apr 15 2024 | 2024 Q1 | CHTR, CNC, FI, IQV, RKT LN | - | - | - |
| Jan 28 2024 | 2023 Q4 | - | - | - | - |
| Oct 10 2023 | 2023 Q3 | CNHI, GOOG | - | - | - |
| Jun 30 2023 | 2023 Q2 | COP, DHR, GOOG | - | - | - |
| Mar 31 2023 | 2023 Q1 | AIG, GOOG, ICE | - | - | - |
| Dec 31 2022 | 2022 Q4 | AMZN, COF, HCA | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
E-commerceSeveral investments in e-commerce leaders across Asia and Latin America, including MercadoLibre, Sea Limited and Alibaba, faced a more competitive operating environment during the period. As long-term investors, SGA observes that competitive intensity in these markets tends to ebb and flow over shorter time horizons, with market leaders typically emerging from such periods with strengthened strategic positions given inherent network effects. |
Marketplaces Competition Network Effects Asia Latin America |
PharmaceuticalsEli Lilly represents a high-quality growth franchise in global healthcare, with leadership in diabetes, obesity, and neuroscience providing durable competitive advantages. The company's GLP-1 treatments continue to see demand outpace supply with additional indications on the horizon. |
Pharmaceuticals GLP1 Diabetes Obesity Healthcare | |
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
Software |
||
Telecom |
||
| 2025 Q2 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
IndustrialsThe fund increased exposure to high-quality industrial businesses with potential for cyclical upturn. Added Quanta Services for AI data center build-out, Hubbell for electrical grid upgrades, Old Dominion for freight cycle recovery, and Waste Connections for secondary market focus. |
Infrastructure Automation Transportation Electrical Equipment Waste Management | |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Fund Letters | William C. Nygren | BAYN GR | Bayer AG | Health Care | Pharmaceuticals | Bull | Xetra | litigation, pharmaceuticals, pipeline, turnaround, valuation | Login |
| Jan 13, 2026 | Fund Letters | William C. Nygren | BABA | Alibaba Group Holding Limited | Consumer Discretionary | Internet & Direct Marketing Retail | Neutral | New York Stock Exchange | AI, cloud, ecommerce, Margins, Subsidies | Login |
| Jan 13, 2026 | Fund Letters | William C. Nygren | SAN FP | Sanofi S.A. | Health Care | Pharmaceuticals | Bull | Euronext Stock Exchange | biologics, pharma, pipeline, vaccines, valuation | Login |
| TICKER | COMMENTARY |
|---|---|
| BABA | Alibaba was a detractor during the quarter after the company reported mixed fiscal Q2 results. While cloud revenue growth accelerated and margins remained stable, the core commerce business struggled with slowing growth and significant profit pressure, particularly in the quick commerce segment where heavy investment and intense competition led to a sharp decline in profitability. |
| BAYRY | This pharmaceutical, agricultural and consumer health conglomerate has been a meaningful investment for the Global Fund for several years. Since inception, it has delivered very poor investment returns for the Fund. Happily, 2025 brought a change in fortunes for the company and the share price. Two of the key areas of investor concern about the company – a patent cliff in its pharmaceutical business, and ongoing costly litigation in its agriculture business – showed some very positive developments. In the former area, sales of some of its new drugs brought to market recently have been growing very strongly, and there were some very positive developments in the company's pipeline. In the agricultural business, there were finally judgements in the company's favour which have the potential to draw a line under the ongoing litigation. After dismal share price performances in 2023 and 2024, the Bayer share price approximately doubled during 2025. |
| CHTR | Weakest performers included Charter Communications (-24%) |
| CNHI | CNH Industrial detracted across the Funds, reflecting investors' continued concerns about the downturn of the Ag cycle and its impact on end-market demand. CNH remains significantly undervalued in our view, and we are adding to our position opportunistically. We took advantage of a pricing opportunity and added to CNH Industrial, which is now a top 10 holding in all four funds. |
| GOOGL | In the third quarter, Google, Kairos Power, and the Tennessee Valley Authority announced a major collaboration centered on a novel power purchase agreement. Google followed this announcement with another significant step forward. On October 27, Google and NextEra Energy announced plans to restart the Duane Arnold Energy Center. |
| IQV | IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company's role as a mission-critical infrastructure to drug development remains unchallenged. The first leg of the industry's recent rally was sparked by stabilization, rewarding patience through a prolonged industry downturn. We expect the next leg to gain steam as the recovery accelerates. |
| RHHBY | Roche (RHHBY) was another positive performer in 2025, driven by a robust pipeline of new and innovative drugs making it to market and favorable regulatory approvals. |
| SNY | Sanofi is a global pharmaceutical company developing biologics, vaccines and healthcare solutions to prevent and treat a wide range of conditions in immunology, hemophilia, rare diseases and general medicine. We think there is a lot to be excited about as management has prioritized innovation by aggressively investing in research and development to cultivate a pipeline of promising products. Despite strong fundamentals, the stock has been weighed down by a volatile year for the vaccine market, investor concerns about patent cliffs and minimal value ascription to its pipeline. This created the opportunity for us to invest in a company we believe is improving, with a long runway for future growth as vaccine markets normalize and new product potential is realized. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||